Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
FOMX was delisted on the 6th of March, 2020.
3 hedge funds and large institutions have $0 invested in Foamix Pharmaceuticals Ltd. Ordinary Shares in 2020 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 59 closing their positions.
95% less funds holding
Funds holding: 65 → 3 (-62)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
100% less capital invested
Capital invested by funds: $95.3M → $0 (-$95.3M)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 59
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
-$37.3M |
| 2 |
DA
DSC Advisors
Chicago,
Illinois
|
-$11.2M |
| 3 |
O
OrbiMed
New York
|
-$8.59M |
| 4 |
MP
Mangrove Partners
Greenwich,
Connecticut
|
-$5.93M |
| 5 |
Morgan Stanley
New York
|
-$4.69M |
FOMX Hedge Fund Activity: Q1 2020 in Review
3 of the 4,547 institutional investors tracked by Wall St. Rank reported a position in Foamix Pharmaceuticals Ltd. Ordinary Shares (FOMX) for Q1 2020, worth a combined $0 — down 100% from $95.3M a quarter earlier.
Sellers outnumbered buyers: 59 funds closed out of FOMX and 0 opened new positions — a net loss of 59 holders — while 1 trimmed existing stakes and 0 added.
The largest seller was Perceptive Advisors, exiting entirely with an estimated $37.3M sold.
- 3 institutional investors held Foamix Pharmaceuticals Ltd. Ordinary Shares (FOMX) as of Q1 2020, down from 65 in Q4 2019.
- Funds reported $0 of Foamix Pharmaceuticals Ltd. Ordinary Shares stock for Q1 2020, down 100% quarter-over-quarter.
- 0 funds opened new Foamix Pharmaceuticals Ltd. Ordinary Shares positions in Q1 2020 and 59 closed out, a net change of -59 holders.
- The largest Foamix Pharmaceuticals Ltd. Ordinary Shares seller in Q1 2020 was Perceptive Advisors, an estimated $37.3M sold.
Based on aggregated 13F filings for Q1 2020.